Two ultra-long acting drugs receive promising news! Phase 1 clinical trials are expected to be completed next year!

R&D Progress /

Immunwork announced that two ultra-long-acting drugs developed using innovative fatty acid bundles technology platform have received approval from the Australian Human Research Ethics Committee in May. TE-8105 targets obesity (including weight management), type 2 diabetes, and fatty liver disease, while TE-8214 targets neuroendocrine tumors and acromegaly. Both drugs have undergone initial dosing in low-dose subjects, […]

Two ultra-long acting drugs receive promising news! Phase 1 clinical trials are expected to be completed next year! Read More »

The 2024 Tang Prize is awarded to three scientists for the development of GLP-1

Reported /

The 2024 Tang Prize in Biopharmaceutical Science has cast a spotlight on GLP-1 receptor agonists, sparking a global race among pharmaceutical companies. TE-8105 of Immunwork, an ultra-long-acting GLP-1 drug, is set to initiate its Phase I clinical trial in Australia, promising significant potential for future development! News website link: 1. https://www.chinatimes.com/newspapers/20240624000185-260202?utm_source=iii_news&utm_medium=rss&chdtv 2. https://www.chinatimes.com/newspapers/20240620000187-260202?chdtv

The 2024 Tang Prize is awarded to three scientists for the development of GLP-1 Read More »

Our latest research result is published in Advanced Science

Scientific Publication /

Exciting news! Our latest published paper offers promising solutions for multiple myeloma treatment through ADC technology platform! We are thrilled to announce the publication of our paper “An Antibody-Drug Conjugate for Multiple Myeloma Prepared by Multi-Arm Linkers” in the prestigious Advanced Science journal. Led by Dr. Allen Yueh-Hsiang Yu, our Senior Manager of Preclinical Development

Our latest research result is published in Advanced Science Read More »

Join Our presentation at the prestigious J.P. Morgan Healthcare Conference

Meeting /

Our Chairman, Dr. Tse-Wen Chang and VP of R&D, Dr. Hsing-Mao Chu are honored speakers at the prestigious J.P. Morgan Healthcare Conference on Februry 21-22, 2024.  Dr. Chang and Dr. Chu will share company updates, provide invaluable perspectives, and introduce revolutionary tech platforms and drug candidates. 

Join Our presentation at the prestigious J.P. Morgan Healthcare Conference Read More »

FDA approves Xolair as first and only medicine for children and adults with one or more food allergies

Reported /

Congratulations to our founder, Dr. Tse-Wen Chang, the inventor of Xolair.We are thrilled to learn that Xolair’s potential benefits are extending to more patients, especially those with food allergies. The website link: https://www.businesswire.com/news/home/20240215550080/en/FDA-Approves-Xolair-as-First-and-Only-Medicine-for-Children-and-Adults-With-One-or-More-Food-Allergies

FDA approves Xolair as first and only medicine for children and adults with one or more food allergies Read More »

Immunwork 2024 Investor Meeting – Results Presentation

News /

The founder of Immunwork and T-E Meds, Dr. Tse-Wen Chang, shared the latest developments of the two companies on 11th January. He further announced Immunwork’s planned entry into the clinical stage in 2024. The two long-acting drugs, TE-8105 and TE-8214, are designed to target type-II diabetes, obesity, fatty liver diseases, and neuroendocrine tumors (NETs) as

Immunwork 2024 Investor Meeting – Results Presentation Read More »

Join our presentation at the World ADC San Diego 2023

Meeting /

Dr. Hsing-Mao Chu, CEO at T-E Meds, will be presenting at the prestigious World ADC conference in San Diego on October 16th (Monday) from 4:30 PM to 5:00 PM. He will unveil our groundbreaking joint technology of “Drug Bundles” and “Glycan Modification” in the applications of ADCs. He will also show how this innovative approach enables precise site-specific

Join our presentation at the World ADC San Diego 2023 Read More »

Scroll to Top